

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Etofibrate

Item No. 21022

CAS Registry No.: 31637-97-5

Formal Name: 3-pyridinecarboxylic acid,

2-[2-(4-chlorophenoxy)-2-methyl-

1-oxopropoxy]ethyl ester

Synonym: Nicotinic Acid $C_{18}H_{18}CINO_5$ MF:

FW: 363.8 **Purity:** ≥98%

UV/Vis.: λ_{max} : 222, 263 nm A crystalline solid Supplied as:

-20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Etofibrate is supplied as a crystalline solid. A stock solution may be made by dissolving the etofibrate in the solvent of choice. Etofibrate is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of etofibrate in ethanol and DMSO is approximately 80 mg/ml and approximately 50 mg/ml in DMF.

Etofibrate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, etofibrate should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Etofibrate has a solubility of approximately 0.1 mg/ml in a 1:5 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Etofibrate is a combination of niacin and clofibrate (Item No. 10956) that acts as a hypolipidemic agent. 1 In vivo, etofibrate decreases plasma cholesterol and triglyceride concentrations and increases bile cholesterol content in rats.^{1,2} It also decreases thromboxane formation, platelet aggregation, and plasma viscosity and inhibits neointima formation in a carotid artery balloon injury rat model.³ Formulations containing etofibrate have been used to treat hyperlipidemia.

References

- 1. Bocos, C., Orozco, E., Castro, M., et al. Effect of etofibrate on bile production in the normolipidemic rat. Gen. Pharmacol. 26(3), 537-542 (1995).
- Herrera, E., Lasunción, M.A., Castro, M., et al. Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism. Biochim Biophys. Acta. 963(1), 42-52 (1988).
- Kinscherf, R., Metz, J., and Wülfroth, P. Etofibrate suppresses neointima formation of the ballooned common carotid artery of rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 352(4), 424-428 (1995).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 08/24/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM